DemeRx Cleared by FDA for First U.S. Clinical Trial of Noribogaine

DemeRx Cleared by FDA for First U.S. Noribogaine Trial

DemeRx is launching the first U.S. clinical trial for its ibogaine-derived drug candidate, noribogaine, following FDA clearance for first-in-human testing in late April. This marks a pivotal moment for a psychedelic long associated with significant safety concerns, particularly cardiotoxicity. DemeRx aims to demonstrate noribogaine's improved safety profile, as it reportedly lacks the psychoactive "trip" effects of ibogaine. The company plans to initiate a Phase 2 trial for alcohol use disorder early next year, building on a recently completed Phase 1 study in the U.K. that showed noribogaine was safe and well-tolerated, with a dose-related QTc increase not considered clinically relevant. This development is supported by growing federal and state momentum for psychedelic therapies, including a recent executive order.

• DemeRx is advancing noribogaine, an active metabolite of ibogaine, specifically to address the significant cardiotoxicity and neurotoxicity concerns associated with the parent compound. The company asserts that noribogaine lacks the "trip" effects and reduces safety risks, aiming to prove this in an alcohol interaction trial preceding a Phase 2 study. A completed Phase 1 study in the U.K. involving 55 healthy volunteers supported its safety and tolerability, noting a dose-related QTc increase that was not clinically relevant.
• The FDA's clearance for noribogaine's first U.S. in-human testing follows a surge in federal and state support for psychedelic therapies. President Donald Trump signed an executive order accelerating psychedelic drug development, and states like Texas, Mississippi, West Virginia, Oklahoma, and Tennessee introduced laws supporting ibogaine clinical trials. This political backing, including discussions with figures like Joe Rogan, has created a more favorable environment for companies like DemeRx, despite ongoing regulatory scrutiny regarding safety and efficacy.
• DemeRx plans to launch a Phase 2 trial for alcohol use disorder early next year, with aspirations for Phase 3 trials by 2028, viewing noribogaine as a potential "pipeline in a drug" due to its potential antidepressant and anti-anxiety effects. To fuel these trials, the company intends to raise $25 million in a Series B financing round set to close this quarter. This funding is critical for advancing noribogaine through the clinic and demonstrating a manageable cardiac safety profile to the FDA.

The Persistent Challenges in Alcohol Use Disorder Treatment

Treatment for Alcohol Use Disorder (AUD) is hampered by a combination of low real-world uptake, modest therapeutic effect sizes, and significant methodological limitations in the supporting evidence base. Despite the availability of both pharmacological and psychosocial interventions, translation from clinical trial efficacy to routine care remains poor, with systemic gaps in screening, intervention, and prescribing practice.

• Critically low treatment engagement and prescription rates: In 2019, only 7.3% of Americans with AUD received any treatment, and just 1.6% were prescribed pharmacotherapy. Among adults with AUD who accessed ambulatory care (74.4%), screening occurred in only 52.5% of cases, brief intervention in 13.5%, and formal treatment in 6.8% — representing a substantial missed opportunity in high-contact healthcare settings.

• Moderate efficacy of approved pharmacotherapies: The four FDA-approved agents — disulfiram, acamprosate, oral naltrexone, and extended-release injectable naltrexone — demonstrate inconsistent outcomes across trials. Number-needed-to-treat figures are modest: NNT = 11 for acamprosate to prevent return to any drinking, and NNT = 18 for oral naltrexone (50 mg/d) for the same endpoint. Injectable naltrexone was associated with fewer drinking days (weighted mean difference: −4.99 days; 95% CI, −9.49 to −0.49), but effect sizes across the class remain limited.

• High relapse burden during and after treatment: Approximately 40% of patients return to drinking during active treatment. While the hazard of a first relapse declines steadily over 42 days of abstinence, the hazard of subsequent relapses following an initial event remains stable — indicating that relapse risk does not diminish meaningfully once the pattern is established. Both first and recurrent relapses are positively associated with the number of DSM-5 AUD criteria met.

• Significant non-adherence and retention challenges: Non-adherence is a pervasive issue in both pharmacological and behavioral trials, with AUD studies particularly vulnerable to discontinuation. High heterogeneity in retention outcomes across psychosocial intervention trials precluded pooled estimates (e.g., brief interventions: I² = 94%; other psychosocial interventions: I² = 77%), underscoring the difficulty of drawing reliable conclusions about treatment persistence.

• Insufficient and low-certainty evidence for psychosocial interventions: For brief interventions and other psychosocial modalities (CBT, contingency management, relapse prevention), evidence quality was rated very low due to extreme heterogeneity (I² up to 98%). Combined pharmacological and psychosocial approaches showed a modest benefit over psychosocial intervention alone (SMD = −0.43; 95% CI: −0.61 to −0.24), but this is based on low-certainty evidence across only four trials.

• Systematic neglect of sex and gender differences: Substantial differences in treatment response between sexes and genders are documented, yet these factors are rarely systematically addressed in clinical trial design or routine clinical care. Existing reviews frequently exclude gender-diverse populations, leaving a critical evidence gap.

• Adverse effect profiles that may limit adherence: Acamprosate is associated with significantly higher rates of diarrhea (RR = 1.58; 95% CI, 1.27–1.97), while naltrexone is linked to elevated nausea (RR = 1.73; 95% CI, 1.51–1.98) and vomiting (RR = 1.53; 95% CI, 1.23–1.91) — tolerability concerns that may contribute to non-adherence in real-world settings.

• Broad evidentiary limitations across the field: Risk of bias is substantial across all intervention categories, with primary threats including lack of blinding and high or differential attrition rates. Significant heterogeneity in outcomes, comparators, and intervention designs renders it difficult to draw generalizable conclusions, and current evidence is insufficient to definitively establish the efficacy of most pharmacological or psychosocial interventions for reducing harmful alcohol use.

Noribogaine's Safety Profile: Mitigating Ibogaine's Cardiotoxicity

In the most recent clinical trial — a randomized, double-blind, placebo-controlled single ascending-dose study published in 2018 — noribogaine was evaluated in 27 patients established on methadone opioid substitution therapy (OST) who had been switched to morphine. Participants received oral doses of 60, 120, or 180 mg (n = 6 per dose level) or matching placebo (n = 3 per dose level). Noribogaine was overall well tolerated across all dose levels. The most frequently reported treatment-emergent adverse events were noneuphoric changes in light perception occurring approximately one hour postdose, headache, and nausea. Pharmacokinetic analysis demonstrated dose-linear increases in AUC and C_max, with slow elimination reflected by a mean half-life range of 24–30 hours. An efficacy signal was also observed, with a nonstatistically significant trend toward reduced opioid withdrawal ratings, most notably at the 120 mg dose level, though the study design was acknowledged to have potentially confounded the evaluation of time to resumption of OST.

A key safety consideration identified in the trial was a concentration-dependent increase in the QTcI interval of 0.17 ms/ng/mL, yielding largest observed mean QTc prolongations of approximately 16, 28, and 42 milliseconds in the 60, 120, and 180 mg groups, respectively. This dose-dependent cardiac effect underscores the importance of cardiac monitoring in noribogaine development programs, and exposure-controlled multiple-dose studies have been planned to further characterize both safety and optimal trial design parameters.

Complementing the clinical data, preclinical rat studies from 2001 and 2006 provided important comparative safety insights between noribogaine and its parent compound, ibogaine. Unlike ibogaine, which produced dose-related increases in tremors and forepaw treading, noribogaine did not elicit either of these adverse neuromotor effects. While both compounds produced significant elevations in plasma corticosterone and prolactin, ibogaine was the more potent stimulator of corticosterone secretion, indicating a more pronounced stress-axis activation profile. Taken together, the preclinical and clinical data suggest that noribogaine carries a more favorable tolerability profile than ibogaine — particularly with respect to tremorigenic liability and neuroendocrine stress activation — positioning it as a potentially safer candidate for further therapeutic development.

Noribogaine's U.S. Debut: A Safer Path for Psychedelic Addiction Therapy

The launch of DemeRx's U.S. clinical trial for noribogaine represents a critical juncture in the evolving landscape of addiction treatment, particularly for alcohol use disorder (AUD). For decades, ibogaine, the parent compound, has been recognized for its potent anti-addictive properties in preclinical models, showing promise in reducing alcohol, opioid, and stimulant self-administration. However, its severe cardiotoxicity, including QTc prolongation and risk of fatal arrhythmias, coupled with its profound hallucinogenic effects, has largely confined it to unregulated settings.

Noribogaine aims to decouple these therapeutic benefits from the dangerous side effects, offering a non-psychoactive derivative with a potentially improved safety profile. This strategic move by DemeRx could unlock a new therapeutic paradigm. By focusing on a compound that modulates neuroplasticity through mechanisms like GDNF upregulation and serotonergic actions, noribogaine offers a novel approach to AUD, a condition where current pharmacotherapies often have limited efficacy. The initial Phase 1 data from the U.K., indicating a dose-related QTc increase not considered clinically relevant, provides a crucial early signal of improved safety. However, the historical context of ibogaine's cardiotoxicity means that subsequent trials will face intense scrutiny regarding cardiovascular safety, demanding meticulous patient screening and monitoring.

The broader 'psychedelic renaissance' provides a tailwind, with increasing federal and state momentum for these therapies. Yet, the path forward is not without its complexities. Proving sustained efficacy in human AUD, beyond initial safety, will be paramount. Furthermore, navigating the regulatory environment for a psychedelic-derived compound, even a non-hallucinogenic one, will require robust data and clear communication to address lingering skepticism and ensure appropriate clinical integration. If successful, noribogaine could establish a precedent for developing safer, more accessible psychedelic-inspired medicines, transforming treatment options for millions struggling with addiction.